A Study of MGC026 in Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06242470

Public ClinicalTrials.gov record NCT06242470. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 3:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.

Study identification

NCT ID: NCT06242470
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: MacroGenics; Industry
Enrollment: 250 participants

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 5, 2024
Primary completion: Apr 30, 2028
Completion: Sep 30, 2028
Last update posted: Aug 10, 2026

2024 – 2028

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
The Angeles Clinic and Research Institute	Los Angeles	California	90025	Recruiting
START Midwest	Grand Rapids	Michigan	49546	Recruiting
START-New York Long Island	Lake Success	New York	11042	Recruiting
Providence Cancer Institute	Portland	Oregon	97213	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
University of Texas Health Science Center at Houston	Houston	Texas	77030	Recruiting
START Mountain Region	West Valley City	Utah	84119	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06242470, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 10, 2026 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06242470 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →